Apollo Medical Holdings and Fresenius Medical Care Partner to Improve the Health of ApolloMed ACO Patients with End-Stage Renal

  Apollo Medical Holdings and Fresenius Medical Care Partner to Improve the
        Health of ApolloMed ACO Patients with End-Stage Renal Disease

PR Newswire

GLENDALE, Calif. and WALTHAM, Mass., May 14, 2013

GLENDALE, Calif.and WALTHAM, Mass., May 14, 2013 /PRNewswire/ --Apollo
Medical Holdings, Inc. ("ApolloMed") (OTCQB: AMEH), a physician-driven
integrated health care delivery company and Fresenius Medical Care (NYSE:
FMS), North America's largest provider of kidney care services, announced
today that ApolloMed's subsidiary, ApolloMed ACO (Accountable Care
Organization), is teaming with Fresenius Medical Care to provide integrated
health care management for its patients with end stage renal disease (ESRD).

Health care for patients with ESRD is often poorly coordinated and expensive
because of these patients' multiple comorbid conditions. ApolloMed ACO is
partnering with Fresenius Medical Care to provide the highly specialized
quality care these patients require.

As part of the agreement, ApolloMed ACO and Fresenius Medical Care will share
in operations and financial cost savings from the partnership. The
multi-year agreement is built on the successful five-year demonstration
project that Fresenius Health Partners, a subsidiary of Fresenius Medical
Care, conducted with Medicare beneficiaries on dialysis.

"We are excited to be partnering with Fresenius Medical Care to work together
on providing best-in-class quality care and management for our ESRD patients,"
stated Warren Hosseinion, M.D., Chief Executive Officer of Apollo Medical
Holdings, Inc. "ApolloMed has been delivering high-quality care at an
efficient cost since 2001. Our growing ACO subsidiary is a valuable next step
in maturing from a hospitalist business into a physician-driven integrated
healthcare delivery company."

"ApolloMed is an outstanding organization which recognizes that an organized
and coordinated approach to caring for patients with kidney disease can make a
big difference in the quality of their health," said Peter Sauer, President,
Fresenius Health Partners. "Our partnership with ApolloMed will allow us to
combine our collective expertise to provide the highest quality and cost
effective care for these individuals."

About Apollo Medical Holdings, Inc.

Headquartered in Glendale, California and dedicated to putting the 'Patient
First,' ApolloMed is a physician-driven integrated healthcare delivery
company, fueled by its commitment to provide exceptional multi-disciplinary
care in the communities it serves in Southern and Central California.
ApolloMed is addressing the healthcare needs of the nation's largest
population center by leveraging its integrated healthcare delivery platform
through its complementary physician groups: ApolloMed Hospitalists and
ApolloMed ACO (Accountable Care Organization). This platform combines
hospitalist medicine, critical care medicine, patient care coordination, case
management and transition managementthat enable healthcare organizations to
engage in performance payments for utilization efficiency, quality of care
objectives and shared accountability arrangements.ApolloMed strives to
improve medical outcomes with high quality, cost efficient care.For more
information, please visitwww.apollomed.net.

About Fresenius Medical Care North America

Through our leading network of more than 2,100 dialysis facilities in North
America and our vascular access centers, laboratory, pharmacy and affiliated
hospitals and nephrology practices, Fresenius Medical Care provides renal
services to hundreds of thousands of people throughout the United States,
Mexico and Canada. We are also the continent's top producer of dialysis
equipment, dialyzers and related disposable products and a major supplier of
renal pharmaceuticals. For more information about the company, visit
www.fmcna.com; for information about patient services, visit
www.ultracare-dialysis.com.

Safe Harbor Statement

This press release may contain forward-looking statements, including
information about management's view of future expectations, plans and
prospects for Apollo Medical Holdings, Inc. ("the Company"). In particular,
when used in the preceding discussion, the words "predicts," "believes,"
"expects," "intends," "seeks," "estimates," "plans," "anticipates," and
similar conditional expressions or future or conditional verbs such as "will,"
"may," "might," "should," "would" and "could" are intended to identify
forward-looking statements. In addition, our representatives may from time to
time make oral forward-looking statements. Any such statements, other than
those of historical fact, about an action, event or development, are
forward-looking statements.Such statements are based on the current
expectations and certain assumptions of the Company's management. Such
statements are, therefore, subject to a variety of known and unknown risks,
uncertainties and other factors, many of which are beyond the control of the
Company, which could cause the actual results, performance or achievements of
the Company, its subsidiaries and concepts to be materially different than
those that may be expressed or implied in such statements or anticipated on
the basis of historical trends. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
the Company's actual results, performance or achievements may vary materially
from those described in the relevant forward-looking statement as being
expected, anticipated, intended, planned, believed, sought, estimated or
projected. Unknown or unpredictable factors also could have material adverse
effects on the Company's future results. The forward-looking statements
included herein are made only as of the date hereof. The Company cannot
guarantee future results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these forward-looking
statements. Finally, the Company undertakes no obligation to update or revise
these forward-looking statements to reflect the impact of circumstances or
events that arise after the date the forward-looking statement was made,
except as required by law, and also takes no obligation to update or correct
information prepared by third parties that are not paid for by the Company.
You should not place undue reliance on any forward-looking statement and
should consider the uncertainties and risks discussed under Item 1A. "Risk
Factors" of the Company's Annual Report on Form 10-K for the year ended
January 31, 2013 and in any of the Company's other subsequent Securities and
Exchange Commission filings.

Media contacts:
Jon Stone, Fresenius Medical Care      Dodi Handy, Apollo Medical Holdings,
                                       Inc.
jonathan.d.stone@fmc-na.com            AMEH@hanoverelite.com
781-699-9704 (o) / 781-392-4680 (cell) 407-585-1080



SOURCE Apollo Medical Holdings, Inc.

Website: http://www.apollomed.net